



29 January 2026

Quarterly Activity Report - Period ending 31 December 2025

Skin Elements Limited (ASX: SKN) (Skin Elements, the Company), a world leader in the development of Australian all natural antimicrobial biotechnology, is pleased to provide its Quarterly Activity Report for the quarter ending 31 December 2025.

Quarterly Highlights

- **SE Formula Biotechnology Commercialisation Ready**
The SE Formula antimicrobial biotechnology formulae continue to meet milestone completions in readiness for initial product commercialisation.
- **ECO Nurture Kiwifruit Evaluation Complete**
With 6,400 litres of ECO-Nurture sustainable, horticultural plant biostimulant delivered to kiwifruit orchards in New Zealand over the 2024 and 2005 growing season, the Company is now seeking to appoint a commercial partner for market rollout for the 2026 going forward.
- **R&D Funding Underpins Development Costs**
The Company received R&D Rebate of \$610k in relation to qualifying R&D expenditure for the FY 2025 year.
- **Strategic Placement raising \$2.5 million completed**
Skin Elements completed a \$2.5 million placement to sophisticated investors following shareholder approval. Funds to accelerate growth and launch into commercialisation.
- **Directors and Key Management settle \$1.0 million debt for equity**
Shareholders approved the issue of securities to a director and key management to settle \$1 million in outstanding remuneration.

Commenting on the quarter, Skin Elements Executive Chairman Mr Peter Malone said;

"Skin Elements delivered a strong quarter, with a robust financial position enhanced by our recent \$2.5 million placement. With this foundation, our sales programmes are well positioned to drive growth in 2026. Strong field evaluation outcomes from our SE Formula SuprCuvr natural TGA medical disinfectant, and ECO Nurture agriculture bio-stimulant programmes, together with independent laboratory verification of our Soleo Organics sunscreen formulations, validate our development process and readiness for commercial scale sales."

SE Formula™ – the Natural Biotechnology Platform

The Company's proprietary SE Formula™ biotechnology platform underpins all product development activities. The SE Formula™ developed in the Company's laboratories is a ground up

Natural Science by Skin Elements

1242 Hay Street, West Perth
Western Australia, 6005
P 08 6311 1900

www.sknlife.com.au
www.skinelementslimited.com
info@skinelementslimited.com

research programme undertaken over an intensive 20 year research period and is the core of the Company's five commercial product platforms.

To date, the Company has developed five highly effective core **GREEN - Tech** formulas, producing award winning, environmentally safe plant-based alternatives with specifications tested in real world applications, outperforming widely used chemical based products in consumer, industrial and agriculture markets.

The SE Formula forms the basis of Skin Elements' product range:

Elizabeth Jane Natural Cosmetics,
Soléo Organics sun protection,
PapayaActivs therapeutics skincare,
SuprCuvr cleaners and disinfectants, and
ECO-Nurture horticultural plant biotstimulant,

Products with the SE Formula™ have scientifically proven efficacy while using only natural and plant-based ingredients and have come to be trusted by consumers. They have all completed phase three development and will all now be readied for commercialization as formula, products or joint venture programmes.

ECO-Nurture Kiwifruit Evaluation Complete

ECO-Nurture is a sustainable, horticultural plant bio stimulant technology that is as an effective alternative to chemical-based agricultural sprays currently used in crop disease protection globally.

Over the past three growing seasons, over 6,400 litres of ECO-Nurture concentrate have been delivered to 120 kiwifruit orchards in New Zealand for application and assessment, with positive outcomes on kiwifruit plant protection and productivity without any chemical residue. A number of orchard managers have incorporated ECO Nurture into their kiwifruit spray protection programmes and ECO Nurture has been approved under Zespri Crop Allowed Other Compounds (AOC) Approval List. Headquartered in New Zealand, Zespri is the world's largest marketer of kiwifruit with over \$5 billion in sales annually.

Skin Elements continues to progress certification for the widespread adoption of ECO-Nurture for the New Zealand kiwifruit industry under approved Zespri Crop Protection Standards and is preparing for commercial roll-out of ECO-Nurture for the 2026 New Zealand kiwifruit growing season.

SuprCuvr high performance disinfectant cleaner

SuprCuvr is a TGA registered hospital-grade disinfectant made from the Company's proprietary 100% plant-based formula.

SuprCuvr is listed on the TGA's Australian Register of Therapeutic Goods (ARTG) in Australia and has Ministry of Primary Industry (MPI) registration in New Zealand.

Following a two year assessment, Spotless has adopted SuprCuvr for daily cleaning and disinfecting of suburban train carriages and stations in the Metro Trains Melbourne urban rail network, supplied and distributed by Bunzl Victoria (MCS facilities) global business cleaning and disinfectant solutions group.

Over the past two years, over 6,000 litres of SuprCuvr concentrate high performance 3 in 1 surface cleaner, glass cleaner and disinfectant cleaner has been delivered to Spotless for evaluation of cleaning and disinfecting train services and high schools in Melbourne. Spotless, a wholly owned

subsidiary of Downer EDI Ltd, is the largest integrated facilities service provider throughout Australia and New Zealand across government, education, healthcare and aged care.

Soléo Organics Sunscreen Delivers Performance

Soléo Organics is an award-winning, natural and organic sunscreen formulation, providing a highly effective, high performance chemical-free sunscreen range. It was the first application borne out of Skin Elements' SE Formula™ research and development program. Soleo Organics has been rated as the number one sunscreen globally out of 1,800 sunscreens by Environmental Working Group (EWG), Washington Post (Sprig) N°1 sunscreen, a finalist in the Clean Beauty Awards, the UK Global Health & Pharma Awards – Best Natural Sunscreen Brand and most recently independently verified by Consumer NZ. Soleo Organics sunscreen formulations are independently tested and certified by the world's leading testing laboratory to ensure reliability and integrity. Products are sold through the Company's online store.

PapayaActivs Therapeutics high concentration skincare

PapayaActivs combines a high concentration of natural pawpaw extract with other active natural ingredients to help relieve the symptoms of skin conditions, like psoriasis, rashes, eczema, assist in healing of minor burns and wounds, and relieve mild muscle, joint and arthritic pain. PapayaActivs is listed on the ARTG and is available through the Company's online store.

Elizabeth Jane Natural Cosmetics

Elizabeth Jane Natural Cosmetics (EJNC) is an extensive range of cosmetic skin repair products that utilise a range of responsible sourced ultra-high end natural ingredients formulated to protect, nourish and revitalise damaged skin. EJNC has been extensively test marketed globally and will be included in the future commercialisation programs.

Research & Development Rebate and Radium Facility Underpins Development Costs

The Company's innovative research and development programmes for its natural SE Formula™ Biotechnology sees it eligible for the Federal Government's R&D Rebate applicable to qualifying R&D expenditure.

During the quarter, Skin Elements received the R&D Rebate of \$610k in relation to qualifying R&D expenditure for the FY 2025 year. The Company also repaid \$433k previously advanced by Radium Capital against this R&D Rebate.

\$2.5m Strategic Placement Strengthens Financial Position

During the quarter Skin Elements completed a \$2.5 million (before costs) capital raising through a two tranche placement to professional and sophisticated investors at \$0.002 per share. Tranche One of \$315,000 was issued under the Company's ASX LR7.1 and 7.1A capacity, with Tranche Two of \$2,185,000 completed following shareholder approval obtained at the Company's 2025 Annual General Meeting.

The placement proceeds will enable the Company to drive towards commercialisation of its product range which is underpinned by its award winning SE Formula™ all natural antimicrobial biotechnology, and provide additional working capital.

The Company issued shares (and free attaching options) at \$0.002 per share to 62 capital Pty Ltd for Lead Manager fees of \$150,000 on the placement.

In addition, the Company issue shares (with free attaching options) at \$0.002 to key director and management to settle \$1 million in outstanding remuneration. Subsequently, a further \$750,000 was raised by the conversion of 125,000,000 options at \$0.006 per share.

Summary of Operating Cashflows

The Company's progression through the development program is reflected in the operating cashflows for the quarter, which included R&D Rebate of \$610k and customer receipts of \$56k. Operational cash outflows included \$470k invested in product manufacturing, staff, research & development, and \$428k for marketing, premises, administration and corporate finance costs. This includes \$141k paid in the quarter to Directors for service fees. Net cash outflows from operating activities for the quarter were \$300k. The Company continues to manage operational cashflows in line with operational and financing cash inflows.

This announcement has been approved by the Board of Directors of Skin Elements Limited.

END

For further information please contact

Peter Malone
Executive Chairman
Skin Elements Limited
T: +61 439 430 770

E: peter@skinelementslimited.com

Media and Investor Inquiries

James Moses
Mandate Corporate
T: +61 420 991 574

E: james@mandatecorporate.com.au

About Skin Elements

Skin Elements (ASX: SKN) is an award winning Australian owned and operated ASX-listed natural biotechnology company focused on the development of its SE Formula™ Biotechnology. Skin Elements world leading innovative approach to research and development of plant-based and organic sourced ingredients has enabled the creation of a portfolio of all natural plant based formulations that have global applications. Its flagship formulations have delivered products that include the SuprCuvr listed on ARTG, hospital-grade plant-based disinfectant, ECO-Nurture plant bio-stimulant, Soléo Organics natural and organic sunscreen, PapayaActivs natural therapeutics skincare products and the Elizabeth Jane Natural Cosmetics brand.

Further information is available via the Company website: <http://skinelementslimited.com> and on the Company online store: www.sknlife.com.au.



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

SKIN ELEMENTS LIMITED (ASX:SKN)

ABN

90 608 047 794

Quarter ended (Current quarter)

31 December 2025

Consolidated statement of cash flows

	Current Quarter \$A'000	Year to date (6 Months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	56	183
1.2 Payments for:	-	-
(a) research and development	(367)	(387)
(b) product manufacturing and operating costs	(34)	(41)
(c) advertising and marketing	(12)	(12)
(d) leased assets	(17)	(35)
(e) staff costs	(79)	(171)
(f) administration costs	(289)	(289)
(g) corporate costs	(119)	(158)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(49)	(50)
1.6 Income taxes (paid) / refunded	-	-
1.7 Government grants and tax incentives	610	610
1.8 Other: (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(300)	(350)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-

2.6 Net cash from / (used in) investing activities	-	-
--	---	---

Consolidated statement of cash flows	Current Quarter \$A'000	Year to date (6 Months) \$A'000
3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	2,500	2,500
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	750	750
3.4 Transaction costs related to issues of equity securities or convertible debt securities	(39)	(39)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	(1,186)	(1,189)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	2,025	2,022
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	7	60
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(300)	(350)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	2,025	2,022
4.5 Effect of movement in exchange rates on cash held	-	-
4.6 Cash and cash equivalents at end of period	1,732	1,732

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	1,732	7
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details):	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,732	7

6. Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1 Aggregate amount of payments to related parties and their associates included in item 1	141
6.2 Aggregate amount of payments to related parties and their associates included in item 2	Nil

Note: if any amounts are shown in items 6.1 and 6.2 your quarterly activity report must include a description of, and an explanation for, such payments

During the quarter \$141k was paid to Directors for service fees.

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify):	-	-
7.4 Total financing facilities	-	-

7.5 **Unused financing facilities available at quarter end** nil

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(300)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	1,732
8.3 Unused finance facilities available at quarter end (Item 7.5)	nil
8.4 Total available funding (Item 8.2 + Item 8.3)	1,732
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	5.77

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. *Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?*

Answer:

N/A

2. *Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?*

Answer:

N/A

3. *Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?*

Answer:

N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: Thursday, 29 January 2026

Authorised by: Board of directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.